{"id":"W2133389067","doi":"10.1200/jco.2007.14.2372","title":"Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Prednisone; Regimen; Cyclophosphamide; Refractory (planetary science); Internal medicine; Multiple myeloma; Gastroenterology; Surgery; Urology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002015525,0.001870538,0.002236311,0.0004265351,0.0004031088,0.0008035869,0.0009490986,0.001072965,0.003201002],"category_scores_gemma":[0.0009232791,0.0004977717,0.0008974245,0.0004372679,0.001062258,0.0004870008,0.0004203652,0.003212872,0.0007626133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009756358,"about_ca_system_score_gemma":0.001575341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008669561,"about_ca_topic_score_gemma":0.001813715,"domain_scores_codex":[0.999348,0.0003889175,0.00003179604,0.00008465128,0.00005722332,0.00008943772],"domain_scores_gemma":[0.9991025,0.000135144,0.0001906363,0.00005232852,0.00003600334,0.0004834023],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8294898,0.05281241,0.009091515,0.0008190862,0.001438161,0.0005246397,0.0002830386,0.002300326,0.0279515,0.0002175346,0.004028167,0.07104381],"study_design_scores_gemma":[0.7408252,0.246366,0.007855395,0.00003698183,0.0002552161,0.0003058466,0.00003208735,0.0009412621,0.00186853,0.0001045655,0.001394724,0.00001426491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930186,0.002398185,0.0003442448,0.0005223752,0.0001187796,0.001927349,0.0004040013,0.00007459953,0.001191985],"genre_scores_gemma":[0.9889446,0.001694061,0.001598021,0.001090683,0.0002661966,0.002296482,0.001900895,0.00002113325,0.002188002],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003201002,"threshold_uncertainty_score":0.01070845,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1545208364887073,"score_gpt":0.4762083366351059,"score_spread":0.3216875001463986,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}